City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced that it has entered into a strategic collaboration with global eye health leader Bausch + Lomb focused on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) that causes irreversible vision loss. Through
Read More

Modivcare Raises $105 Million in Incremental Financing Backed by Stakeholders Across the Capital Structure and Takes Strategic Steps to Position Business for the Future

DENVER–(BUSINESS WIRE)–Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company providing a platform of integrated supportive care solutions focused on improving health outcomes, today announced key initiatives to support future growth. The Company has secured $75 million in incremental financing, backed by stakeholders across the capital structure, and appointed Chad Shandler as its Chief Transformation Officer. An existing investor, Coli
Read More

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available
Read More

Eating fiber-rich foods could help prevent harmful gut bacteria growth

The group of bacteria called Enterobacteriaceae, including Klebsiella pneumoniae, Shigella, E. coli and others, is present at low levels as part of a healthy human gut microbiome. But at high levels—caused, for example, by increased inflammation in the body, or by eating contaminated food—these bugs can cause illness and disease. In extreme cases, too much Enterobacteriaceae in the gut can be life-threatening.
Read More
Top